Literature DB >> 15031736

First dose of potential new medicines to humans: how animals help.

Peter Greaves1, Andrew Williams, Malcolm Eve.   

Abstract

The need for careful testing of new drugs in animal models before study in humans has been recognised by physicians since the First World War. Now, first human studies on new drugs are subject to detailed government guidelines, which in the European Union are presently being reinforced through the wide-ranging Clinical Trials Directive. However, despite their long history and widespread application, these guidelines are empirical and have been formulated with a paucity of critical scientific evidence. Here, we review the principles and the available, albeit limited, evidence that support the design and conduct of preclinical studies in a way that permits effective and safe first-dose studies of potential new medicines in humans.

Entities:  

Mesh:

Year:  2004        PMID: 15031736     DOI: 10.1038/nrd1329

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  32 in total

Review 1.  Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism.

Authors:  Thomas A Baillie; Allan E Rettie
Journal:  Drug Metab Pharmacokinet       Date:  2010-10-22       Impact factor: 3.614

2.  How do researchers decide early clinical trials?

Authors:  Hannah Grankvist; Jonathan Kimmelman
Journal:  Med Health Care Philos       Date:  2016-06

3.  Surveying the literature from animal experiments.

Authors:  Roger Lemon; Stephen B Dunnett
Journal:  BMJ       Date:  2005-04-30

Review 4.  Medical progress depends on animal models - doesn't it?

Authors:  Robert A J Matthews
Journal:  J R Soc Med       Date:  2008-02       Impact factor: 5.344

Review 5.  In vitro platforms for evaluating liver toxicity.

Authors:  Shyam Sundhar Bale; Lawrence Vernetti; Nina Senutovitch; Rohit Jindal; Manjunath Hegde; Albert Gough; William J McCarty; Ahmet Bakan; Abhinav Bhushan; Tong Ying Shun; Inna Golberg; Richard DeBiasio; Berk Osman Usta; D Lansing Taylor; Martin L Yarmush
Journal:  Exp Biol Med (Maywood)       Date:  2014-04-24

6.  Reengineering translational science: the time is right.

Authors:  Francis S Collins
Journal:  Sci Transl Med       Date:  2011-07-06       Impact factor: 17.956

Review 7.  Antibody Drug Conjugates: Nonclinical Safety Considerations.

Authors:  Mary Jane Masson Hinrichs; Rakesh Dixit
Journal:  AAPS J       Date:  2015-05-30       Impact factor: 4.009

8.  Toxicogenomic module associations with pathogenesis: a network-based approach to understanding drug toxicity.

Authors:  J J Sutherland; Y W Webster; J A Willy; G H Searfoss; K M Goldstein; A R Irizarry; D G Hall; J L Stevens
Journal:  Pharmacogenomics J       Date:  2017-04-25       Impact factor: 3.550

9.  Use of silkworms for identification of drug candidates having appropriate pharmacokinetics from plant sources.

Authors:  Yukihiro Asami; Ryo Horie; Hiroshi Hamamoto; Kazuhisa Sekimizu
Journal:  BMC Pharmacol       Date:  2010-06-11

10.  The role of preclinical animal models in breast cancer drug development.

Authors:  Robert Clarke
Journal:  Breast Cancer Res       Date:  2009-12-18       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.